Related references
Note: Only part of the references are listed.Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions
Bellinda L. King-Kallimanis et al.
CLINICAL TRIALS (2019)
Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials
Derek Kyte et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
The use of PRO in adverse event identification during cancer therapy - choosing the right questions to ask
Aase Nissen et al.
ACTA ONCOLOGICA (2019)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Patient reported outcome measures in rare diseases: a narrative review
Anita Slade et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol
Ameeta Retzer et al.
BMJ OPEN (2018)
Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre, non-inferiority trial
K. Beaver et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2017)
Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension
Rebecca Mercieca-Bebber et al.
QUALITY OF LIFE RESEARCH (2017)
CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials
Vivian A. Welch et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials
Vivian A. Welch et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
J. O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2016)
Development and evaluation of a specifically designed website for haematopoietic stem cell transplant patients in Leeds
B. Horne et al.
EUROPEAN JOURNAL OF CANCER CARE (2016)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh Senan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schoffski et al.
LANCET (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Systematic evaluation of patientreported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol
Khaled Ahmed et al.
BMJ OPEN (2016)
Outcomes and endpoints in cancer trials: bridging the divide
Michelle K. Wilson et al.
LANCET ONCOLOGY (2015)
Assessment of patient-reported adverse events after discharge from hospital in RCTs in gastrointestinal cancer surgery: is there sufficient coverage in existing EORTC questionnaires?
Kerry Avery et al.
TRIALS (2015)
Patient-reported measurement of time to diagnosis in cancer: development of the Cancer Symptom Interval Measure (C-SIM) and randomised controlled trial of method of delivery
Richard D. Neal et al.
BMC HEALTH SERVICES RESEARCH (2014)
Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer
Manfred Welslau et al.
CANCER (2014)
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Effectiveness of Acupressure for the Control and Management of Chemotherapy-Related Acute and Delayed Nausea: A Randomized Controlled Trial
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Bryce B. Reeve et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers
Melanie Calvert et al.
PLOS ONE (2014)
Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Acupuncture for Cancer-Related Fatigue in Patients With Breast Cancer: A Pragmatic Randomized Controlled Trial
Alexander Molassiotis et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Use of Patient-reported Outcomes (PRO) Within Comparative Effectiveness Research Implications for Clinical Practice and Health Care Policy
Sara Ahmed et al.
MEDICAL CARE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Content Validity-Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2-Assessing Respondent Understanding
Donald L. Patrick et al.
VALUE IN HEALTH (2011)
Content Validity-Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1-Eliciting Concepts for a New PRO Instrument
Donald L. Patrick et al.
VALUE IN HEALTH (2011)
Advance care planning in advanced cancer: Can it be achieved? An exploratory randomized patient preference trial of a care planning discussion
Louise Jones et al.
PALLIATIVE & SUPPORTIVE CARE (2011)
Dangers in Using Translated Medical Questionnaires The Importance of Conceptual Equivalence Across Languages and Cultures in Patient-Reported Outcome Measures
Raoul Breugelmans
CHEST (2009)
Multinational Trials-Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report
Diane Wild et al.
VALUE IN HEALTH (2009)
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Ethan Basch et al.
LANCET ONCOLOGY (2006)
Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation
D Wild et al.
VALUE IN HEALTH (2005)
Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model - The PRO-ESOR project
A Tennant et al.
MEDICAL CARE (2004)
Share Paper
